Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence NGFKSHALQLNNRQ
Primary information
sequence IDSeq_5626
Peptide sequenceNGFKSHALQLNNRQ
CancerPDF_ID CancerPDF_ID36, CancerPDF_ID905, CancerPDF_ID1051, CancerPDF_ID1921, CancerPDF_ID9612, CancerPDF_ID9934, CancerPDF_ID11945, CancerPDF_ID12711,
PMID16896061,19795908,16395409,21136997,21533267,21124649,26992070,27058005
Protein NameComplement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C4-B,Complement C4-A,Complement C4-A,Complement C4-B,Complement C4
UniprotKB Entry Name"CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4A_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4A_HUMAN
FluidSerum,Plasma,Serum,Serum,Serum,Serum,Serum,Serum
M/Z1626.85,542.95,1626.85,1625.83864,542.95,NA,1625.8386,1626.912
Charge1,3,1,1,3,NA,NA,NA
Mass (in Da)1626.84,NA,NA,NA,NA,NA,1626.850864,NA
fdrNA,NA,NA,NA,NA,1626.8,NA,NA
Profiling TechniqueMALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC-ESI-MS/MS,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,Multiple Reaction Monitoring,NA,NA,NA
Labelled/Label FreeLabel Free,Labelled,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free
FDRNA,less than 7%,less than 1 “5,NA,1.49,NA,FDR 1 %,NA
CancerPDF_ID CancerPDF_ID36, CancerPDF_ID905, CancerPDF_ID1051, CancerPDF_ID1921, CancerPDF_ID9612, CancerPDF_ID9934, CancerPDF_ID11945, CancerPDF_ID12711,
p-Value1.00E-05,NA,4.28E-10,NA,NA,6.69E-12,NA,"less than 0.001,0.058,less than 0.05"
SoftwareMASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,NA,SEQUEST and Maxquant,Proteome Discoverer
Length14,14,14,14,14,14,14,14
Cancer TypeMetastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Lung adenocarcinoma,Breast cancer,Melanoma,Breast cancer
DatabaseNCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4),NCBI Protein Database,SwissProt Database,SwissProt Database
ModificationNA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,9 BC and 9 control,8 cancer samples and 4 healthy samples," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)."
RegulationNA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively",NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs control,"Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples.","Upregulated with the fold change of 0.56 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.80, Upregulated in BC vs healthy with 0.754 fold change"
ValidationIndependent validation,NA,Independent validation,Leave One out Cross validation,MRM-based validation of 19 candidates,NA,na,NA
Sensitivity95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA
Specificity95% on independent dataset,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA
Peptide AtlasNA
IEDB